SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001720725-22-000048
Filing Date
2022-05-05
Accepted
2022-05-05 16:10:00
Documents
64
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q oyst-20220331.htm   iXBRL 10-Q 1003620
2 EX-10.1 exhibit101-linkagreement.htm EX-10.1 92296
3 EX-31.1 oyst-q1x22ex311xnau.htm EX-31.1 12945
4 EX-31.2 oyst-q1x22ex312xlochner.htm EX-31.2 12633
5 EX-32.1 oyst-q1x22ex321xnau.htm EX-32.1 7321
6 EX-32.2 oyst-q1x22ex322xlochner.htm EX-32.2 7878
12 image_0.jpg GRAPHIC 6351
  Complete submission text file 0001720725-22-000048.txt   5581255

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20220331.xsd EX-101.SCH 40095
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oyst-20220331_cal.xml EX-101.CAL 67232
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oyst-20220331_def.xml EX-101.DEF 139131
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20220331_lab.xml EX-101.LAB 544986
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20220331_pre.xml EX-101.PRE 342757
58 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20220331_htm.xml XML 853877
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39112 | Film No.: 22896306
SIC: 2836 Biological Products, (No Diagnostic Substances)